$SAGE: strong base, upcoming catalysts$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here.
Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it breaks to the upside given the technical pattern suggesting the smart money has been accumulating stock.
Upcoming catalysts:
SAGE-217 - (SHORELINE)
Major Depressive Disorder (MDD)
Phase 3 additional data due in mid-2023.
Zuranolone (SAGE-217)
Major depressive disorder (MDD) and Postpartum Depression
PDUFA priority review date of August 5, 2023.
Best of luck!
Cheers,
Ivan Labrie.
